Dyspareunia, Painful Intercourse, in Breast Cancer

Dyspareunia, painful intercourse, in Breast Cancer is a common side effect in BC survivors. Dyspareunia is the topic of this post. I plan to cover other sexual dysfunctions in cancer survivors more broadly in future blog posts.

Painful Intercourse—Potential Causes and Solutions

Dyspareunia (pain with intercourse) is very common in breast cancer survivors, especially those on endocrine therapy (aromatase inhibitors, tamoxifen) or after chemotherapy-induced menopause. The causes are usually hypoestrogenism, vulvovaginal atrophy, pelvic floor dysfunction, and neurogenic pain—so the best results come from layered, multimodal solutions.

Below is a clear, clinically grounded menu of options, from first-line to advanced, with breast-cancer–specific safety notes.

1. Vaginal Dryness & Atrophy (most common cause)

First-line (safe for all breast cancer patients)

Regular vaginal moisturizers (2–3×/week)
- Polycarbophil-based (e.g., Replens-type)
- Hyaluronic acid vaginal gels
Lubricants during intercourse
- Silicone-based (longer-lasting, less friction)
- Avoid glycerin/parabens if recurrent irritation

🧠 Key point: Moisturizers are preventive; lubricants are situational—most patients need both.

Second-line (non-hormonal but restorative)

Vaginal hyaluronic acid suppositories
- Comparable symptom relief to estrogen in some studies
Vitamin E or D vaginal suppositories
Laser or radiofrequency vaginal therapy
- Mixed evidence, but helpful for selected patients
- Best for refractory GSM (genitourinary syndrome of menopause)

2. Low-Dose Vaginal Estrogen (select patients only)

⚠️ Controversial but increasingly supported for severe symptoms

Options:

Ultra-low-dose estradiol tablets or rings
Estriol preparations (minimal systemic absorption)

Key considerations

Avoid or use extreme caution in:
- Active estrogen-receptor–positive disease
- Aromatase inhibitor users (higher concern)
Often acceptable:
- Tamoxifen users (tamoxifen blocks estrogen receptors)
Should be:
- Lowest effective dose
- Co-managed with oncology

📌 Multiple oncology societies now acknowledge that quality-of-life–threatening dyspareunia may justify cautious use.

3. Pelvic Floor Dysfunction (often overlooked)

Very common contributors

Pelvic floor muscle hypertonicity
Vaginismus
Pain amplification after trauma or prolonged avoidance

Effective therapies

Pelvic floor physical therapy
- Gold standard for penetration pain
Vaginal dilator therapy
- Gradual, guided, non-sexual use
Myofascial release & biofeedback

💡 Many patients report dramatic improvement within 8–12 weeks.

4. Neuropathic or Inflammatory Pain

Helpful options

Topical lidocaine (pre-intercourse or nightly)
Low-dose gabapentin (oral or vaginal)
Capsaicin-free compounded creams

Used when pain feels:

Burning
Electric
Out of proportion to exam findings

5. Non-Hormonal Systemic Therapies

Ospemifene (oral SERM)
- Improves vaginal tissue
- ⚠️ Use cautiously; oncology input required
DHEA (prasterone) vaginal suppositories
- Minimal systemic estrogen conversion
- Emerging but promising data

6. Psychosexual & Relationship-Centered Care

Dyspareunia is not purely mechanical—especially after cancer.

Helpful supports:

Sex therapist familiar with cancer survivorship
Cognitive behavioral therapy (CBT)
Mindfulness-based pain reduction
Couples counseling

🧠 Fear–pain–avoidance cycles are biological, not psychological weakness.

7. Lifestyle & Adjunctive Supports

Regular sexual or vaginal activity (maintains elasticity)
Warm compresses before intimacy
Vulvar-safe hygiene only
Omega-3s, hydration, anti-inflammatory diet
Avoid irritants (soaps, douches, fragranced products)

A Practical Step-Up Plan (What Actually Works)

Moisturizer + lubricant
Pelvic floor PT
Hyaluronic acid or vitamin E
Neuropathic pain treatment if needed
Carefully selected vaginal estrogen or DHEA
Psychosexual support

As a long-term cancer survivor of a blood cancer called multiple myeloma, my only goal in researching and writing about side effects is to educate cancer survivors about the side effect, dyspareunia, painful intercourse, in breast cancer, in this case, and then provide possible solutions. As always, knowledge is power.

Scroll down the page, post a question or a comment, if you’d like have questions about breast cancer.

Hang in there,

David Emerson

Cancer Survivor
Cancer Coach
Director PeopleBeatingCancer

A Practical Solution for Dyspareunia in Breast Cancer Survivors: A Randomized Controlled Trial

Abstract

Purpose: Dyspareunia is common in breast cancer survivors because of low estrogen. This study explored whether dyspareunia is introital pain, preventable with analgesic liquid.

Patients and methods: In a randomized, controlled, double-blind trial, estrogen-deficient breast cancer survivors with severe penetrative dyspareunia applied either saline or 4% aqueous lidocaine to the vulvar vestibule for 3 minutes before vaginal penetration. After a 1-month blinded trial of patient-assessed twice-per-week tampon insertion or intercourse, all patients received lidocaine for 2 months in an open-label trial. The primary outcome was patient-related assessment of penetration pain on a scale of zero to 10. Secondary outcomes were sexual distress (Female Sexual Distress Scale), sexual function (Sexual Function Questionnaire), and resumption of intercourse. Comparisons were made with the Mann-Whitney U and Wilcoxon signed rank test with significance set at P < .05.

Results: In all, 46 patients, screened to exclude those with pelvic muscle and organ pain, uniformly had clinical evidence of severe vulvovaginal atrophy, dyspareunia (median pain score, 8 of 10; interquartile range [IQR], 7 to 9), increased sexual distress scores (median, 30.5; IQR, 23 to 37; abnormal, > 11), and abnormal sexual function. Users of lidocaine reported less pain during intercourse in the blinded phase (median score of 1.0 compared with saline score of 5.3; P = .007). After open-label lidocaine use, 37 (90%) of 41 reported comfortable penetration. Sexual distress decreased (median score, 14; IQR, 3 to 20; P < .001), and sexual function improved in all but one domain. Of 20 prior abstainers from intercourse who completed the study, 17 (85%) had resumed comfortable penetrative intimacy. No partners reported penile numbness.

Conclusion: Breast cancer survivors with menopausal dyspareunia can have comfortable intercourse after applying liquid lidocaine compresses to the vulvar vestibule before penetration.

Dyspareunia painful intercourse in Breast Cancer Dyspareunia painful intercourse in Breast Cancer